We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » About 40 Percent of Aduhelm Patients Experienced Brain Swelling, Bleeds
About 40 Percent of Aduhelm Patients Experienced Brain Swelling, Bleeds
More than 40 percent of patients in pivotal phase 3 trials of Aduhelm (aducanumab), Biogen’s FDA-approved Alzheimer’s treatment, experienced either brain swelling or microhemorrhages associated with the now-approved 10 mg/kg dose.